Core Viewpoint - The company reported a significant increase in revenue for the first three quarters of 2025, driven by domestic insulin product sales and international market expansion. Financial Performance - For the first three quarters of 2025, the company's revenue reached 3.047 billion yuan, an increase of 802 million yuan, representing a year-on-year growth of 35.73% [6] - Domestic insulin product sales contributed 2.624 billion yuan, up 822 million yuan from the previous year, with volume and price increases contributing 492 million yuan and 330 million yuan respectively [6][7] - International sales revenue was 353 million yuan, a year-on-year increase of 110 million yuan, or 45.52%, attributed to the company's global strategy and partnerships, particularly in Brazil [6][8] Non-Recurring Gains and Losses - The report indicates that there were non-recurring gains and losses, but specific details on amounts and classifications were not provided [4] Shareholder Information - The company will hold its first extraordinary general meeting of 2025 on November 17, 2025, with both onsite and online voting options available for shareholders [14][15] Governance Changes - The company plans to cancel its supervisory board and amend its articles of association, with the audit committee taking over the supervisory responsibilities [53][54] - The company has proposed updates to its operational scope, including new business areas such as rubber products and medical packaging [55]

Core Viewpoint - Gannee Pharmaceutical reported strong financial performance for the first three quarters of 2025, with significant growth in both revenue and net profit driven by increased sales and prices of insulin products [1] Financial Performance - The company achieved a revenue of 3.047 billion yuan, representing a year-on-year increase of 35.73% [1] - The net profit attributable to shareholders reached 818 million yuan, marking a year-on-year growth of 61.32% [1] Product Performance - Domestic sales of insulin preparations increased compared to the same period last year [1] - Following the continuation of centralized procurement for insulin, the company experienced a rise in the prices of its insulin products, which, along with increased sales volume, significantly contributed to revenue growth [1]

重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人（会计主管人员）周丽保证季度报告中 财务信息的真实、准确、完整。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603087 证券简称：甘李药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 √适用 □不 ...